Biomarkers, CDx & Precision Medicine 2026
.png)
Congress Centre Basel, Switzerland
Where AI Meets Precision Medicine
The AI and Data Zone at Biomarkers, CDx and Precision Medicine Europe and NextGen Omics, Tech and Data 2026 is where the companies building the AI infrastructure of precision medicine meet the scientists putting it to work.
Basel. 13 - 14 October.
Biomarkers, CDx and Precision Medicine Europe and NextGen Omics, Tech and Data 2026 bring together the precision medicine and multi-omics research community in Basel.
Pharma, biotech, spatial biology platforms, diagnostics companies and AI-driven data organisations. The people making platform decisions, evaluating technology partnerships and setting biomarker and omics strategy.
In 2026 the two events co-locate for the first time, creating the most concentrated precision medicine audience at any European event this year.
AI is now embedded across the full biomarker and multi-omics value chain, from target identification and biomarker discovery to spatial data analysis, computational pathology and CDx development.
If your technology sits in AI-powered multi-omics, spatial biology, data infrastructure, precision diagnostics or computational pathology, this is where your buyers are.
A dedicated space within the shared exhibition hall, purpose-built for AI-driven precision medicine, multi-omics data platforms and next-generation spatial and diagnostic technologies.
The Zone is shared across both events. A single destination that draws delegates from both the Biomarkers and CDx programme and the NextGen Omics programme throughout both days. Not a pass-through. A destination.
Live demonstrations
Show your platform working. The actual technology, running in real time, in front of the scientists who need to understand what it does: spatial data analysis, multi-omics integration, AI-assisted pathology or biomarker pipeline automation.
Short technology talks
High-impact, focused presentations designed for a scientific audience with limited time and high standards. Five to ten minutes. One clear idea. The format that works for this community.
Closed-door roundtable: AI in Precision Medicine
An invite-only session with twelve pharma and biotech leaders on the specific challenges and opportunities of applying AI in precision medicine. A hosted discussion with a post-session summary report shared with all participants. Three roundtable sponsorships available.
VR Formula 1 experience
Set against the iconic streets and landmarks of Switzerland, the VR F1 driving experience is the social activation at the heart of the Zone. It draws delegates in, creates a reason to stay and generates repeated brand interactions across both days. Sponsor branding featured on the VR stations throughout.
Barista coffee
A branded barista coffee cart at the heart of the Zone. The most visited point in the space across both days. Logo on the cart and on every recyclable cup served.
Traditional pharma biomarker and translational teams such as AstraZeneca, Roche, Novartis and Novo Nordisk. Running biomarker programmes across oncology, neuroscience and rare disease. Evaluating AI platforms for spatial data analysis, multi-omics integration, CDx development and precision patient stratification.
Spatial biology and multi-omics technology teams Scientists actively building and deploying spatial transcriptomics, proteomics and single cell workflows. Evaluating data analysis platforms, image analysis tools and AI-assisted annotation solutions.
Computational pathology and CDx leaders Organisations bridging the gap between digital pathology, AI and companion diagnostic development. The fastest-growing segment of the precision medicine landscape and one of the most commercially active.
Omics data and bioinformatics organisations From sequencing service providers to AI-driven bioinformatics platforms. The companies and teams making the data generated by the programmes around them scientifically actionable.
Your Zone presence sits inside a two-day scientific programme built entirely around the questions your technology answers.
Biomarkers, CDx and Precision Medicine Europe runs three simultaneous programmes: Biomarkers and Companion Diagnostics, Spatial Biology for Precision Medicine, and Computational Pathology, AI and Precision Diagnostics.
NextGen Omics, Tech and Data runs across Multi-Omics Technologies for Precision Medicine, Multi-Omics in Single Cell and Spatial Analysis, and NextGen Omics Data and Analysis.
Confirmed speakers from AstraZeneca, Roche, GSK, Novartis, Novo Nordisk, Lundbeck, Merck Healthcare KGaA, Bayer, AbbVie, Boehringer Ingelheim and Daiichi Sankyo across tracks covering AI-driven biomarker discovery, spatial biology, computational pathology, CDx regulatory strategy, multi-omics data integration and precision oncology.
There are also invite-only Collaboration Hub sessions for senior leaders on utilising AI in precision medicine, bridging the gap between research and clinical implementation, and next-generation clinical trial design for biomarker-driven therapies.
You are not adjacent to this programme. You are inside it.
Six sponsorship positions are available within the AI and Data Zone across the two co-located events:
Exclusive to one sponsor. Naming rights to the AI and Data Zone. 20-minute in-programme presentation plus keynote slot and live demo within the Zone. Branding on the VR F1 stations and main Zone archway. 14 pre-scheduled one-to-one meetings. 6x2m exhibition space. Full event marketing integration.
Focused Zone presence with full programme access. 20-minute in-programme presentation plus 5-minute slot and live demo within the Zone. 3x2m exhibition space. 7 pre-scheduled one-to-one meetings. Inclusion across the Zone sponsor section of both event websites.
Exclusive to one sponsor. Brand your platform at the heart of Zone social activity. The barista coffee cart is the most visited point in the Zone across both days. Logo on the cart and on every recyclable cup served. Pull-up banner space. Inclusion across event marketing and the Zone sponsor section of both event websites.
Exclusive to three sponsors. Host a closed-door roundtable with twelve pharma and biotech leaders on AI in precision medicine. A moderated discussion with full lead retrieval and a post-session summary report shared with all participants. Zone branding and inclusion across event marketing.
Exclusive to three sponsors. Brand one of three VR Formula 1 stations hosted in the Zone across both days. Pull-up banner position, badge scanning for lead retrieval and brand mention across pre-event communications. Oxford Global hosts a Fastest Driver of the Day competition for repeated delegate engagement throughout both days.
A focused Zone presence for early-stage AI and data platforms. A 5-minute presentation slot and live demo within the Zone. 1x1m cocktail table space. Inclusion across event marketing. Eligibility criteria apply: companies operating for 0-5 years, 1-30 employees, revenue generating under £750k.
All packages include exhibition presence within the Zone, inclusion in event marketing materials and access to the full delegate community across both co-located events.
Traditional pharma R&D — the AstraZenecas, GSKs, Sanofis and Novartises. Integrating AI across discovery pipelines at enterprise scale. Evaluating platforms for target identification, data infrastructure, lab automation and computational chemistry.
Asset-centric and platform biotech — AI-embedded from the start. Often faster to evaluate and adopt new technology than large pharma counterparts.
AI-native drug developers — companies like Recursion, Insilico Medicine and BenevolentAI who are building the new paradigm. They attend to collaborate, benchmark and find pharma partners.
Your Zone presence sits inside a two-day scientific programme built entirely around the questions your technology answers. Keynote speakers include Dave Hallett, Chief Scientific Officer of Recursion, on the automation and AI landscape in 2026. Paul Workman OBE FRS of the Institute of Cancer Research on 25 years of precision medicine. Ingo Hartung of Merck Healthcare KGaA on moving beyond inhibitors.
Confirmed speakers from AstraZeneca, GSK, Sanofi, Novartis, Roche, Bayer, AbbVie, Novo Nordisk and Boehringer Ingelheim across tracks covering AI-guided drug discovery, automation, computational chemistry, screening, targeted protein degradation, ADC development and neuroscience.
There are also invite-only closed-door sessions for senior leaders on where smart capital is flowing in drug discovery, the real impact of AI on workflows, and the winning model for brain health innovation.
You are not adjacent to this programme. You are inside it.